Research project
Functional Specialisation of SUMO4 in Human Cell Signalling
- Start date: 24 August 2026
- End date: 23 August 2029
- Funder: BBSRC C/o RCUK Shared Services
- Value: 1,078,418.98
- Primary investigator: Dr Alexander Garvin
Project title
Functional Specialisation of SUMO4 in Human Cell Signalling
Description
Cells use molecular tags to control how proteins behave. One such tag is called SUMO (Small Ubiquitin-like Modifier), which helps regulate essential processes like DNA repair, gene expression, and immune responses. Most SUMO proteins (SUMO1–3) work by attaching to other proteins — a process called SUMOylation. Disruptions in this system are linked to diseases such as cancer and inflammation. This project focuses on SUMO4, a lesser-known member of the SUMO family. Unlike its relatives, SUMO4 cannot attach to other proteins and was long thought to be inactive. However, my recent research shows that SUMO4 plays a critical role in cell signalling without needing to attach — acting instead as a “pseudoSUMO” that influences other proteins, especially SENP1, an enzyme that removes SUMO tags. Importantly, there are two common forms of SUMO4 in the human population, caused by a small genetic difference. These forms behave differently: one boosts SENP1 activity, while the other does not. This project will explore how these variants affect NFκB signalling, a key pathway in inflammation and immune responses. We will also study their impact on pancreatic beta-cells, which produce insulin and are crucial for controlling blood sugar.